Statement: More than 3 patients in the primary trial had a common cold.
Primary_evidence: Adverse Events 1:   Total: 2/81 (2.47%)   Heart failure 0/81 (0.00%)   Fever 1/81 (1.23%)   Cold 0/81 (0.00%)   Catheter related infection (Bacteriemia) 0/81 (0.00%)   Lack of strength in left leg 0/81 (0.00%)   Ostenecrosis produced by biphosphonates 0/81 (0.00%)   Gastric cancer 0/81 (0.00%)   Stroke 0/81 (0.00%)   Hematuria 1/81 (1.23%)   Nodule in left breast 0/81 (0.00%) Adverse Events 2:   Total: 10/85 (11.76%)   Heart failure 1/85 (1.18%)   Fever 0/85 (0.00%)   Cold 1/85 (1.18%)   Catheter related infection (Bacteriemia) 1/85 (1.18%)   Lack of strength in left leg 1/85 (1.18%)   Ostenecrosis produced by biphosphonates 1/85 (1.18%)   Gastric cancer 1/85 (1.18%)   Stroke 1/85 (1.18%)   Hematuria 0/85 (0.00%)   Nodule in left breast 1/85 (1.18%)